Timothy Perren

14.4k total citations · 1 hit paper
151 papers, 6.6k citations indexed

About

Timothy Perren is a scholar working on Reproductive Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Timothy Perren has authored 151 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Reproductive Medicine, 61 papers in Oncology and 37 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Timothy Perren's work include Ovarian cancer diagnosis and treatment (69 papers), Intraperitoneal and Appendiceal Malignancies (28 papers) and Cancer Treatment and Pharmacology (21 papers). Timothy Perren is often cited by papers focused on Ovarian cancer diagnosis and treatment (69 papers), Intraperitoneal and Appendiceal Malignancies (28 papers) and Cancer Treatment and Pharmacology (21 papers). Timothy Perren collaborates with scholars based in United Kingdom, Canada and Australia. Timothy Perren's co-authors include Peter J. Selby, Gordon C. Jayson, P Selby, Rosamonde E. Banks, Sean Kehoe, Matthew Nankivell, Jane Hook, Mahesh Parmar, David Luesley and Sharadah Essapen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Timothy Perren

148 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

2015 945 citations Sean Kehoe, Jane Hook et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy Perren United Kingdom	42	3.0k	2.2k	1.4k	1.3k	902	151	6.6k
Paul Sabbatini United States	45	4.0k 1.3×	2.5k 1.1×	1.8k 1.3×	1.5k 1.1×	1.9k 2.1×	182	8.8k
Noriyuki Katsumata Japan	38	2.8k 0.9×	1.3k 0.6×	776 0.5×	1.2k 0.9×	811 0.9×	183	5.7k
Claire F. Verschraegen United States	46	3.0k 1.0×	1.2k 0.5×	2.0k 1.4×	1.1k 0.8×	1.5k 1.7×	267	6.9k
Linda Mileshkin Australia	40	3.2k 1.1×	1.2k 0.5×	1.6k 1.1×	558 0.4×	938 1.0×	273	6.6k
Clemens Tempfer Austria	52	1.9k 0.6×	2.6k 1.2×	1.9k 1.3×	2.1k 1.6×	796 0.9×	374	9.2k
Fedro A. Peccatori Italy	49	4.7k 1.6×	2.1k 1.0×	1.4k 1.0×	565 0.4×	806 0.9×	260	8.7k
Alexander Reinthaller Austria	46	2.2k 0.7×	2.4k 1.1×	1.3k 0.9×	2.1k 1.6×	895 1.0×	273	7.2k
Scott Wadler United States	43	4.5k 1.5×	1.1k 0.5×	2.0k 1.4×	1.9k 1.4×	1.9k 2.1×	192	8.1k
Susana Banerjee United Kingdom	43	3.6k 1.2×	2.4k 1.1×	2.1k 1.4×	609 0.5×	852 0.9×	307	7.0k
R. Kreienberg Germany	54	4.3k 1.4×	1.5k 0.7×	2.1k 1.5×	1.3k 1.0×	1.3k 1.5×	434	10.6k

Countries citing papers authored by Timothy Perren

Since Specialization

Citations

This map shows the geographic impact of Timothy Perren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Perren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Perren more than expected).

Fields of papers citing papers by Timothy Perren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Perren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Perren. The network helps show where Timothy Perren may publish in the future.

Co-authorship network of co-authors of Timothy Perren

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Perren. A scholar is included among the top collaborators of Timothy Perren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Perren. Timothy Perren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Symeonides, Stefan N., Duncan Wheatley, Stephen Chan, et al.. (2023). Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment. 199(1). 35–46. 8 indexed citations

You, Benoît, Michel Tod, Gabe S. Sonke, et al.. (2020). 815MO The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients. Annals of Oncology. 31. S616–S616. 3 indexed citations

Vergote, Ignace, Corneel Coens, Matthew Nankivell, et al.. (2019). Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials. Obstetrical & Gynecological Survey. 74(3). 156–158. 30 indexed citations

Hall, Marcia, Gianfilippo Bertelli, Clare Green, et al.. (2019). Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. International Journal of Gynecological Cancer. 30(2). 213–220. 19 indexed citations

McNeish, Iain A., Andrew Dean, David Gallardo, et al.. (2017). ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis. Annals of Oncology. 28. v627–v627. 38 indexed citations

Perren, Timothy, W. Schroeder, Éric Pujade-Lauraine, et al.. (2013). ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. UCL Discovery (University College London). 21 indexed citations

Ledermann, JA, Timothy Perren, Andrew Embleton-Thirsk, et al.. (2013). Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. UCL Discovery (University College London). 75 indexed citations

Pujade-Lauraine, Éric, Timothy Perren, Sven� Mahner, et al.. (2013). ICON7: FINAL OVERALL SURVIVAL RESULTS IN THE GCIG PHASE III RANDOMISED TRIAL OF BEVACIZUMAB IN NEWLY DIAGNOSED OVARIAN CANCER. UCL Discovery (University College London). 6 indexed citations

Hall, Marcia, Charlie Gourley, Iain A. McNeish, et al.. (2013). Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer. 108(2). 250–258. 59 indexed citations

10.

Ledermann, Jonathan A., Allan Hackshaw, Gordon C. Jayson, et al.. (2011). Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Journal of Clinical Oncology. 29(28). 3798–3804. 164 indexed citations

11.

Rustin, Gordon, Nicholas Reed, Gordon C. Jayson, et al.. (2011). A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology. 22(11). 2411–2416. 23 indexed citations

12.

Perren, Timothy, Jacobus Pfisterer, JA Ledermann, et al.. (2010). ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC). UCL Discovery (University College London). 34 indexed citations

13.

Vasudev, Naveen, David A. Cairns, Geoff Hall, et al.. (2010). The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Archives of Gynecology and Obstetrics. 284(1). 221–227. 27 indexed citations

14.

Leo, Angelo Di, Minna Tanner, Christine Desmedt, et al.. (2007). p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Annals of Oncology. 18(6). 997–1003. 49 indexed citations

15.

Dent, Judith, Geoff Hall, Nafisa Wilkinson, et al.. (2003). Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. British Journal of Cancer. 88(10). 1578–1583. 26 indexed citations

16.

Kessel, David, et al.. (2002). Routine Chest Radiography Following Imaging‐Guided Placement of Tunneled Central Lines: A Waste of Time, Money, and Radiation. Nutrition in Clinical Practice. 17(2). 105–109. 4 indexed citations

17.

Perren, Timothy, Marius von Knoch, & P Matter. (2001). Bruchverhalten von AO-3,5-mm-Kortikalis-Titanschrauben (Synthes®-Schrauben) in Kombination mit LC-DCP-Platten. Zeitschrift für Orthopädie und ihre Grenzgebiete. 139(3). 256–260. 2 indexed citations

18.

Perren, Timothy, et al.. (1997). A phase II study of recombinant interferon-β (r-hIFN-β 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. British Journal of Cancer. 75(3). 423–426. 5 indexed citations

19.

Gore, M., Vincent Lévy, Gordon Rustin, et al.. (1995). Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. British Journal of Cancer. 72(4). 1016–1019. 45 indexed citations

20.

O’Brien, E, Timothy Perren, Sylvia Tan, Cyril Fisher, & E. Wiltshaw. (1994). The endodermal sinus tumour and clear cell ovarian cancer. Annals of Oncology. 5(8). 753–756. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact